Google+ Facebook Twitter Twitter

IBMS contributes to Parliamentary pandemic report

Following the IBMS evidence submission and President Allan Wilson’s presentation to an All-Party Parliamentary Group (APPG) coronavirus inquiry, a parliamentary report has been published.

The biggest review to date of the UK’s response to coronavirus urges the government to adopt a “COVID-secure” exit strategy or risk a third spike in the New Year.

The IBMS has been listed as a key contributor in the cross-parliamentary new COVID-secure exit strategy, following the submission of evidence and Allan Wilson’s appearance at the APPG hearing last October.

The APPG was set up in July 2020 to conduct a rapid inquiry into the government’s handling of the pandemic.

Its purpose is to ensure that lessons are learned and to issue recommendations to the government “so that its preparedness and response may be improved in future”.

The report contains 71 key findings and makes 44 recommendations, which are termed “more important than ever”.

A key recommendation is the urgent need for a nationwide exit strategy, which acknowledges that by saving people’s lives, the UK, in turn, safeguards jobs and the economy.

It adds that the government needs to adopt the COVID-secure UK plan, to suppress the virus and then catch new cases at UK entry points, while the vaccine programmes are rolled out.  

The report and recommendations can be accessed by visiting

Image Credit | Shutterstock

Related Articles

Rethink the lateral flow test roll-out?

Professor Iain Buchan argues that lateral flow tests have been misunderstood and are a useful tool in the fight against COVID-19.

Diagnostic legislation changes

Pathology Quality Manager Jessica Dixon looks at safety and quality assurance practices in relation to expanded testing due to the pandemic.

First test for all known human coronaviruses

Scientists at the Centre for Infection and Immunity (CII) at Columbia University Mailman School of Public Health and Sun Yat-sen University in China have set the stage for the development of highly sensitive antibody tests for infection with all known human coronaviruses, including new variants of SARS-CoV-2.